Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Eli Lilly and Company will pay $47.5 million for the rights to Centrexion Therapeutics’ nonopioid chronic pain treatment, CNTX-0290. The small molecule, currently in Phase I trials, modulates the somatostatin receptor type 4, part of a protein family that dampens the activity of several types of pain receptors. Centrexion could get another $575 million in development and regulatory milestones and can buy into commercializing the drug in the US alongside Lilly.
This article has been sent to the following recipient: